PNLIPRP1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse Pancreas tissue lysate, Primary antibody: P08629(PNLIPRP1 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P08629(PNLIPRP1 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The PNLIPRP1 antibody targets pancreatic lipase-related protein 1 (PNLIPRP1), a member of the pancreatic lipase family encoded by the *PNLIPRP1* gene. PNLIPRP1 is primarily expressed in the pancreas and shares structural homology with classical pancreatic lipase (PNLIP) but exhibits distinct functional properties. Unlike PNLIP, which hydrolyzes dietary triglycerides, PNLIPRP1 lacks lipase activity and may act as an inhibitor or modulator of lipid digestion, potentially regulating lipase activity or lipid absorption in the intestine. Its precise physiological role remains under investigation, though it is implicated in lipid metabolism and pancreatic function.

Antibodies against PNLIPRP1 are essential tools for studying its expression, localization, and interactions in research settings. They enable detection via techniques like Western blotting, immunohistochemistry, and ELISA, aiding in explorations of its role in pancreatic disorders, metabolic syndromes, or digestive diseases. Some studies suggest PNLIPRP1 may serve as a biomarker in pancreatic pathologies, including chronic pancreatitis or pancreatic cancer, though clinical applications are still exploratory. Commercial antibodies are typically validated for specificity against conserved epitopes, with cross-reactivity assessments across species. Researchers prioritize antibodies with high affinity and minimal background noise to ensure accuracy in both qualitative and quantitative analyses. Further studies are needed to clarify PNLIPRP1's mechanistic contributions and therapeutic potential.